Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC) CEO Spiro Rombotis joined Proactive at the Biotech Showcase 2020 in San Francisco. The New Jersey-based company recently announced preliminary data from two of the company’s Phase 1 studies aiming to treat patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes and chronic lymphocytic leukemia.
Cyclacel Pharmaceuticals CEO reveals key milestone data
Quick facts: Cyclacel Pharmaceuticals Inc
Price: 4.76 USD
Market Cap: $23.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE